Progress of Pharmacological Approaches in Parkinson's Disease

Clin Pharmacol Ther. 2019 May;105(5):1106-1120. doi: 10.1002/cpt.1374. Epub 2019 Mar 22.

Abstract

The progressive neurodegenerative process in Parkinson's disease (PD) is not restricted to dopaminergic midbrain neurons but involves the entire nervous system. In this review, we outline established treatment options at different disease stages and address new therapeutic approaches. These include, based on recent advances in the understanding of the pathophysiology of PD, genetic and disease-modifying approaches to reduce abnormal accumulation and aggregation of alpha-synuclein (aSYN), mitochondrial dysfunction, and dysfunction of lysosomal proteins. Moreover, we highlight clinical trials to reduce neuroinflammation and increase neurorestoration.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use*
  • Dopamine Agents / therapeutic use
  • Humans
  • Neuroprotective Agents
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / genetics

Substances

  • Antiparkinson Agents
  • Dopamine Agents
  • Neuroprotective Agents